Arcturus Therapeutics (ARCT) Short Interest Ratio & Short Volume → Things Are Not Normal in America – Here’s What to Do (From Stansberry Research) (Ad) Free ARCT Stock Alerts $26.79 -0.42 (-1.54%) (As of 05/9/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media Arcturus Therapeutics Short Interest DataCurrent Short Volume4,610,000 sharesPrevious Short Volume4,810,000 sharesChange Vs. Previous Month-4.16%Dollar Volume Sold Short$135.12 millionShort Interest Ratio / Days to Cover9.7Last Record DateApril 15, 2024Outstanding Shares26,928,000 sharesFloat Size24,560,000 sharesShort Percent of Float18.77%Today's Trading Volume548,718 sharesAverage Trading Volume460,820 sharesToday's Volume Vs. Average119% Short Selling Arcturus Therapeutics ? Sign up to receive the latest short interest report for Arcturus Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatARCT Short Interest Over TimeARCT Days to Cover Over TimeARCT Percentage of Float Shorted Over Time Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. Arcturus Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20244,610,000 shares $135.12 million -4.2%18.8%9.7 $29.31 3/31/20244,810,000 shares $162.43 million +14.3%19.6%10.6 $33.77 3/15/20244,210,000 shares $152.87 million -0.2%17.2%10 $36.31 2/29/20244,220,000 shares $163.57 million -6.6%17.3%10.1 $38.76 2/15/20244,520,000 shares $172.62 million +3.4%18.6%11.4 $38.19 1/31/20244,370,000 shares $144.08 million +5.3%18.0%10.3 $32.97 Get the Latest News and Ratings for ARCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20244,150,000 shares $137.57 million +0.5%17.1%9.8 $33.15 12/31/20234,130,000 shares $130.22 million -6.8%17.0%10.1 $31.53 12/15/20234,430,000 shares $127.94 million -18.4%18.2%10.9 $28.88 11/30/20235,430,000 shares $129.99 million +7.1%22.3%13.5 $23.94 11/15/20235,070,000 shares $114.18 million +1.6%20.8%13.1 $22.52 10/31/20234,990,000 shares $95.31 million +4.2%20.6%13.6 $19.10 10/15/20234,790,000 shares $109.79 million +3.9%19.8%12.3 $22.92 9/30/20234,610,000 shares $117.79 million +10.0%19.0%10.8 $25.55 9/15/20234,190,000 shares $119.58 million +6.6%17.3%9.4 $28.54 8/31/20233,930,000 shares $119.28 million +0.3%16.2%8.8 $30.35 8/15/20233,920,000 shares $117.36 million +2.1%16.2%8.9 $29.94 7/31/20233,840,000 shares $134.25 million +5.8%15.9%8.6 $34.96 7/15/20233,630,000 shares $128.65 million +9.0%15.0%8.4 $35.44 6/30/20233,330,000 shares $95.50 million -8.0%13.8%7.7 $28.68 6/15/20233,620,000 shares $99.48 million +0.3%15.0%6.8 $27.48 5/31/20233,610,000 shares $98.70 million +8.7%15.0%7 $27.34 5/15/20233,320,000 shares $101.69 million +5.7%13.8%6.4 $30.63 4/30/20233,140,000 shares $83.59 million +11.7%13.7%6.4 $26.62 4/15/20232,810,000 shares $77.47 million +6.0%12.3%5.9 $27.57 3/31/20232,650,000 shares $63.52 million +4.3%11.6%5.8 $23.97 3/15/20232,540,000 shares $40.49 million +8.6%11.1%7.5 $15.94 2/28/20232,340,000 shares $38.03 million +4.9%10.2%5.8 $16.25 2/15/20232,230,000 shares $41.32 million +21.9%9.8%5.5 $18.53 1/31/20231,830,000 shares $38.67 million +9.6%8.0%3.8 $21.13 1/15/20231,670,000 shares $33.20 million -12.1%7.3%2.9 $19.88 12/30/20221,900,000 shares $32.22 million -27.8%8.3%3.3 $16.96 12/15/20222,630,000 shares $47.97 million -7.4%11.5%4.5 $18.24 11/30/20222,840,000 shares $52.37 million +9.2%12.4%5.2 $18.44 11/15/20222,600,000 shares $46.80 million -10.0%11.4%4.8 $18.00 10/31/20222,890,000 shares $51.15 million +9.5%12.6%5.6 $17.70 10/15/20222,640,000 shares $37.75 million +6.0%11.5%6.2 $14.30 9/30/20222,490,000 shares $36.90 million +9.7%10.9%5.7 $14.82 9/15/20222,270,000 shares $37.18 million +1.3%9.9%4.9 $16.38 8/31/20222,240,000 shares $31.45 million -14.2%9.8%4.1 $14.04Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. ARCT Short Interest - Frequently Asked Questions What is Arcturus Therapeutics' current short interest? Short interest is the volume of Arcturus Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 4,610,000 shares of ARCT short. 18.77% of Arcturus Therapeutics' shares are currently sold short. Learn More on Arcturus Therapeutics' current short interest. What is a good short interest ratio for Arcturus Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ARCT shares currently have a short interest ratio of 10.0. Learn More on Arcturus Therapeutics's short interest ratio. Which institutional investors are shorting Arcturus Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Arcturus Therapeutics: Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Arcturus Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 18.77% of Arcturus Therapeutics' floating shares are currently sold short. Is Arcturus Therapeutics' short interest increasing or decreasing? Arcturus Therapeutics saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 4,610,000 shares, a decline of 4.2% from the previous total of 4,810,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Arcturus Therapeutics' float size? Arcturus Therapeutics currently has issued a total of 26,928,000 shares. Some of Arcturus Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Arcturus Therapeutics currently has a public float of 24,560,000 shares. How does Arcturus Therapeutics' short interest compare to its competitors? 18.77% of Arcturus Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Arcturus Therapeutics: Cogent Biosciences, Inc. (13.04%), PureTech Health plc (0.02%), SIGA Technologies, Inc. (12.30%), Aurinia Pharmaceuticals Inc. (8.91%), Y-mAbs Therapeutics, Inc. (7.04%), Disc Medicine, Inc. (14.90%), Savara Inc (4.96%), Wave Life Sciences Ltd. (2.58%), Dianthus Therapeutics, Inc. (8.87%), Mineralys Therapeutics, Inc. (3.77%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Arcturus Therapeutics stock? Short selling ARCT is an investing strategy that aims to generate trading profit from Arcturus Therapeutics as its price is falling. ARCT shares are trading down $0.42 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Arcturus Therapeutics? A short squeeze for Arcturus Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ARCT, which in turn drives the price of the stock up even further. How often is Arcturus Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ARCT, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Cogent Biosciences Short Interest PureTech Health Short Interest SIGA Technologies Short Interest Aurinia Pharmaceuticals Short Interest Y-mAbs Therapeutics Short Interest Disc Medicine Short Interest Savara Short Interest Wave Life Sciences Short Interest Dianthus Therapeutics Short Interest Mineralys Therapeutics Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ARCT) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThis 1 Biotech Stock has been shocking the marketsHuge AlertsProof that the Musk/Bezos rivalry is about to hit a new levelInvestorPlaceTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressHe Is Giving Away BitcoinCrypto Swap Profits